Integrin Beta 3 Market is Segmented By Type (MSP-68, OCU-200, AC-301, C-16Y, Others), By Application(Melanoma, Arterial Thrombosis, Diabetic Macular Edema, Cancer, Others), By End-user(Hospital, Clinics, Laboratory, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.
Integrin Beta 3 Market is expected to reach high at a CAGR during the forecast period (2023-2030).
Integrins regulate cellular growth, proliferation, migration, signaling, cytokine activation and release and play a key role in cell proliferation and migration, apoptosis, tissue repair, and all other processes involved in inflammation, infection, and angiogenesis. The ITGB3 protein product is the integrin beta chain beta 3, found along with the alpha IIb chain in platelets.
Integrin Beta 3 Market
|
Metrics |
Details |
|
Market CAGR |
Integrin Beta 3 Market is expected to reach high at a CAGR during the forecast period (2023-2030). |
|
Segments Covered |
By Load, By Distribution Channel, By Vehicle and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click here
Integrin Beta 3 Market Dynamics
Integrins regulating stemness in solid tumours is an emerging therapeutic target expected to drive market growth.
Cancer stemness, which relates to cancer cells with a stem cell (SC)-like phenotype, has long been identified as an important factor in carcinogenesis. Cancer stemness increases with tumour growth in general. A tiny population of stem-like cancer cells (i.e., cancer stem cells, CSCs) can self-renew, differentiate, and initiate tumours among the many subsets of cancer cells seen in a tumour. Mounting evidence has established CSCs as drivers of tumour progression, treatment resistance, disease relapse and metastasis. Therefore, Integrin is needed for SCs to sense and respond to various triggers in both normal and sick tissues as a bridge transferring outside-in and inside-out signals. In support of this, more research has revealed that integrins can act as both phenotypic indicators and functional regulators of CSCs, adding to the complexity of CSC regulation and the possibility of developing integrin-targeted treatments to combat cancer stemness. Thus, from the above statements, the market is expected to drive in the forecast period.
Restraint:
The developed agent's activation of integrin signalling is a major drawback of targeting integrin ligand binding, limiting the clinical success of the integrin ligand-based antagonist/agonist. It is one factor that the market is expected to get hampered in the forecast period.
Global Integrin Beta 3 Market - Industry Analysis
COVID-19 Impact Analysis
The SARS-CoV-2 pandemic resulted in a near-global lockdown and moderately influenced the integrin beta 3 industry. The SARS-CoV-2 spike protein has been shown to bind multiple integrin subtypes. Although there is growing evidence for interactions based on the spike RGD sequence, the exact binding mechanisms are still unknown. Moreover, computational studies suggest that the spike RGD motif is not completely accessible for integrin-binding. At the same time, there have also been other non-RGD-binding integrins that have been suggested to be potentially involved in SARS-CoV-2 viral entry. The motifs comprise potential binding to RGD-binding integrins, such as αVβ6, as well as non-RGD-binding integrins, such as αXβ2. Additionally, hundreds of relevant clinical trials are currently underway worldwide. Numerous research facilities implemented protocols limiting the number of lab employees allowed on-site to reduce the risk of virus transmission, putting many investigations on hold. Thus, the market will undergo impetus growth during the forecast period.
Integrin Beta 3 Market Segment Analysis
Cancer segment is expected to hold the largest market share in integrin beta 3 market.
The cancer segment accounted for the largest market share in 2020. β3 integrin in tumours, the subtype that exhibits the widest range of functions, is αvβ3 integrin. It is associated with the growth, survival, invasion and metastasis of different cancer cells. Moreover, in certain types of cancer, it is an indicator of increased lymph node or bone metastasis and decreased patient survival. Similar to β1 integrin, β3 integrin may also bind with ECM components to form focal adhesions between cancer cells and the ECM. Concomitantly, in suspension, β3 integrin prevents cancer cells from IMD by activating a non-canonical FAK-independent signalling pathway.
Additionally, β3 integrin in endothelial cells can affect the growth of tumours by regulating angiogenesis. Therefore, β3 integrin exhibits the ability to regulate receptor tyrosine kinase (RTK). Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.
Integrin Beta 3 Market Geographical Analysis
North America region holds the largest market share in the global integrin beta 3 market
In 2020, North America accounted for the highest revenue share. The increasing prevalence of cancer and clinical trials carried out by the market players and well-established healthcare facilities in the region are a few factors due to which the market is expected to boost in the forecast period. For instance, according to the American Cancer Society, In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. In contrast, In 2020, an estimated 1,806,590 new cancer cases were diagnosed in the United States, and 606,520 people died from the disease. The three most common cancers for women are breast, lung, and colorectal, and they will account for an estimated 50% of all new cancer diagnoses in 2020. Moreover, Proda Biotech L.L.C. is part of the Drugs and Druggists' Sundries Merchant Wholesalers Industry, located in the U.S.A., has conducted a Phase I study to assess the safety of ProAgio in participants with advanced solid tumour malignancies, including pancreatic cancer. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.
Integrin Beta 3 Market Competitive Landscape
Major key players in the integrin beta 3 market are GenWay Biotech, Cell Signaling Technology, Inc., Synaptic Systems GmbH, Merck KGaA , R&D Systems, Inc., Thermo Fisher Scientific Inc., Proteintech Group, Inc., Abcam plc. and Sino Biological Inc.
GenWay Biotech:
Overview:
GenWay Biotech is a well-known developer of protein and antibody solutions. They have offered a broad catalog of goods and services with proteomic solutions and applications to the research community since 1998. GenWay, a protein and antibody solutions provider has a multi-functional technology platform for functional genomics and proteomics that uses genes, proteins, antibodies, and their applications in cells, tissues, and animal models. GenWay's primary competencies allow them to do bioinformatics analyses on protein targets, manufacture high-quality protein antigens and ligands, and design domain-specific IgY antibodies for immunoaffinity capture, partitioning, detection, and analysis.
Product Portfolio:
Human Integrin Beta3 (Ab-773) Antibody (GWB-ASC722): Integrin beta3 (Ab-773) Antibody detects endogenous levels of total Integrin beta3 protein.
Frequently Asked Questions
What is the Projected CAGR value of the Integrin Beta 3 Market?
Integrin Beta 3 Market is expected to reach high at a CAGR during the forecast period 2023-2030.
Which region controlled the global market during 2023-2030?
North America region Controls the Integrin Beta 3 Market during 2023-2030.
Which is the fastest growing region in the Integrin Beta 3 Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period